AbCellera Biologics (NASDAQ:ABCL – Get Free Report) and Kaya (OTCMKTS:KAYS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.
Volatility & Risk
AbCellera Biologics has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Kaya has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.
Valuation & Earnings
This table compares AbCellera Biologics and Kaya”s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
AbCellera Biologics | $33.05 million | 24.78 | -$146.40 million | ($0.54) | -5.15 |
Kaya | $200,000.00 | 3.88 | $1.61 million | $0.02 | 1.75 |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for AbCellera Biologics and Kaya, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
AbCellera Biologics | 0 | 1 | 3 | 0 | 2.75 |
Kaya | 0 | 0 | 0 | 0 | N/A |
AbCellera Biologics currently has a consensus price target of $10.33, indicating a potential upside of 271.70%. Given AbCellera Biologics’ higher possible upside, equities research analysts plainly believe AbCellera Biologics is more favorable than Kaya.
Profitability
This table compares AbCellera Biologics and Kaya’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
AbCellera Biologics | -463.77% | -13.40% | -10.44% |
Kaya | 260.23% | -9.79% | 652.87% |
Institutional & Insider Ownership
61.4% of AbCellera Biologics shares are held by institutional investors. 28.0% of AbCellera Biologics shares are held by company insiders. Comparatively, 23.5% of Kaya shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Kaya beats AbCellera Biologics on 7 of the 13 factors compared between the two stocks.
About AbCellera Biologics
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
About Kaya
Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.